FDA Grants Dupixent® (dupilumab) Breakthrough Therapy Designation for Eosinophilic Esophagitis
TARRYTOWN, N.Y. and PARIS, Sept. 14, 2020 /PRNewswire/ -- Designation based on positive results from Part A of pivotal Phase 3 trial Dupixent is the first and only biologic to show positive and clinically-meaningful Phase 3 results in patients 12 years and older with eosinophilic...